Receive The Newest Study Notifications

As a part of ClinOne and our CEO’s personal mission, ClinOne will start compensating/reimbursing caregivers of clinical trial participants for their very significant contribution to research, and the incredible amount of support they commit in supporting patients...

– Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with mild to moderate ulcerative colitis –...

Study will evaluate the safety and preliminary efficacy of AR-13503 SR Implant as monotherapy and in combination with aflibercept --  Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and...

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina...

Trial with once a day oral dosing to be conducted in 232 patients with moderate to severe ulcerative colitis at more than 150 sites in over 15 countries Published 9-month interim results of ongoing Phase 2a maintenance study ABX464-102 confirmed durability of safety...

ViewRay Incorporated,  (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized...

Becomes the only clinical logistics provider with fully integrated services RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2019 /PRNewswire/ -- Marken announced today that its nursing services for home-based clinical trials are now operational in most key markets around the...

Trial will evaluate the effectiveness of perivascular sirolimus to improve AV Fistula outcomes in patients with kidney disease Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced...

- Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT") announced today the commencement of a clinical research trial with the GI Research Institute ("GIRI") and the University of British Columbia ("UBC") under the direction of Dr. Brian L. Bressler, MD, as Principal...

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesions of the anus, i.e. anal high-grade...

The US Centers for Disease Control and Prevention (CDC) estimates that the rate of sexually transmitted infections (STI) are on the rise with an estimated 1.7 million cases documented in 2017 in the United States. Although chlamydia can typically be successfully...

Immunic announced the first patient enrolled in a proof-of-concept clinical trial of IMU-838 for the treatment of primary sclerosing cholangitis, according to a press release. The National Institutes of Health awarded a grant to Keith Lindor, MD, principal...

Significantly Positive Phase 2 Results Eliminate Need for High Dose Cohort Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB:KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company's Phase 2 clinical study evaluating...

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it has initiated ReDUX4, a Phase 2b clinical trial of losmapimod in...

On Target Laboratories Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the...

Trial with once a day oral dosing to be conducted in 232 patients with moderate to severe ulcerative colitis at more than 150 sites in over 15 countries Published 9-month interim results of ongoing Phase 2a maintenance study ABX464-102 confirmed durability of safety...

Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma. Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this...

ViewRay, Inc. (VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. This...

Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesions of the anus, i.e. anal high-grade squamous...

As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines. Oncologie and Merck will launch a Phase II trial to investigate Merck’s Keytruda...